Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer

Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer

Bibliographic Details
Main Authors: Rea, D, Gray, R, Bowden, S, Handley, K, Earl, H, Poole, C, Bates, T, Dewar, J, Raytor, Z, Lee, M
Format: Conference item
Published: 2013

Similar Items